A study published by researchers at John Hopkins University (Baltimore , Maryland) concluded that psilocybin, a hallucinogenic drug, causes experiences of “ substantial personal meaning and spiritual significance ” in users. A majority of the participants felt a better sense of well-being, even months after consuming the drug. Researchers expect that the results can be used for further investigation of psychoactive substances and cognition. Thirty volunteers without prior experience with hallucinogens were given psilocybin and methylphenidate (Ritalin) in separate sessions. The Ritalin sessions served as the control group who used that drug as a placebo . The tests were double-blind , with neither the subject nor the administrator knowing which drug was being administered. About 36\% of participants also had a strong to extreme “experience of fear” or dysphoria (eg, a “bad trip” ) at some point during the psilocybin session (which was not reported by any subject during the methylphenidate session), with about one-third of these (13\% of the total) reporting that this dysphoria dominated the entire session. These negative effects were reported to be easily managed by the researchers and did not have a lasting negative effect on the subject’s sense of well-being.
A study published by researchers at (Balitmore , Maryland) concluded that psilocybin, a hallucinogenic drug, causes experiences of " substantial personal meaning and spiritual significance " in users. A majority of the participants felt a better sense of well-being, even months after consuming the drug. Researchers expect that the results can be used for further investigation of psychoactive substances and cognition. Thirty volunteers without prior experience with hallucinogens were given psilocybin and (Ritalin) in separate sessions. The Ritalin sessions served as the control group who used that drug as a . The tests were , with neither the subject nor the administrator knowing which drug was being administered. About 36\% of participants also had a strong to extreme “experience of fear” or (eg, a "" ) at some point during the psilocybin session (which was not reported by any subject during the methylphenidate session), with about one-third of these (13\% of the total) reporting that this dysphoria dominated the entire session. These negative effects were reported to be easily managed by the researchers and did not have a lasting negative effect on the subject’s sense of well-being.
R
John Hopkins University (Baltimore
(Balitmore
R
“
"
R
”
"
D
methylphenidate
D
placebo
D
double-blind
D
dysphoria
R
“bad trip”
""